Target intelligence / Profile preview

Mycobacterial ribosomal protein S1 (RpsA)

Target
RpsA
Molecular classification
Ribosomal protein, RNA-binding protein, Translation initiation factor, Other
01

Overview

Mycobacterial ribosomal protein S1 (RpsA, bS1) is a large, highly acidic, and flexible protein (~61 kDa) found on the small subunit (30S) of the mycobacterial ribosome[1][3][4][5]. Composed of four (in mycobacteria) or up to six (in E. coli/Gram-negatives) oligonucleotide/oligosaccharide-binding (OB)-fold domains, it binds single-stranded RNA and is essential for translation initiation on canonical mRNAs by recruiting and stabilizing binding of the mRNA to the ribosome[1][2][3]. In Mycobacterium smegmatis and Mycobacterium tuberculosis, S1 also interacts with unique rRNA segments to protect and stabilize the ribosome during hibernation, which may help bacterial survival during latency or stress[3]. Ribosomal protein S1 is considered a potential, though currently unexploited, antimicrobial target, owing to its crucial role in protein synthesis and ribosome function in mycobacteria[4]. Past hypotheses about it being the direct target of pyrazinamide have been refuted in recent studies[5].

Other names
Ribosomal protein S1bS1RpsA
02

Mechanism of action

Not applicable: no clinically validated drugs act directly on Mycobacterial ribosomal protein S1. Previously proposed: inhibition of trans-translation by blocking tmRNA binding (no longer supported for clinical drugs).

03

Biological functions

Facilitation of translation initiation by binding mRNARecruitment of mRNA to the ribosome (acts as an "mRNA-catching arm")Recognition of mRNAs with weak or degenerate Shine-Dalgarno sequencesParticipation in trans-translation (ribosome rescue)Structural stabilization of the ribosome, especially during hibernating states in Mycobacteria
04

Disease associations

Infection (notably in Mycobacterium tuberculosis and related species)Other
05

Safety considerations

Targeting ribosomal proteins like S1 poses potential risks for general protein synthesis inhibition in prokaryotes, leading to broad-spectrum antibacterial effects and possible off-target toxicity, but specific safety challenges have not been detailed for anti-S1 strategies in mycobacteria.
06

Interacting drugs

No drugs are currently confirmed to specifically target Mycobacterial ribosomal protein S1 in clinical use

1 more in the full profile.

07

Biomarkers

None known

Beyond the preview

Go deeper on Mycobacterial ribosomal protein S1 (RpsA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mycobacterial ribosomal protein S1 (RpsA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call